

# A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

NCT04853251

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 4
<b>Sponsor</b>	Genentech, Inc.
<b>Enrollment</b>	188 participants

## Key Eligibility Criteria

---

### Inclusion (11)

- Diagnosis of nAMD prior to screening as determined by the investigator
- Difference of  $\leq 10\%$  in ECD at screening between the 2 eyes as measured by specular microscopy and determined by the independent reading center
- Availability of historical visual acuity (VA) data and spectral-domain optical coherence tomography (SD-OCT). Additionally, fluorescein angiography or color fundus photography can both be used to support participant eligibility per protocol at investigator discretion
- Availability of comprehensive historical anti-vascular endothelial growth factor (VEGF) injection data, including agent administered and date of administration from the time of diagnosis, or for at least 2 years prior to screening if diagnosis was made more than 2 years before screening
- Response to at least two prior anti-VEGF IVT injections as determined by the investigator based on the following:  
... and 6 more (see full listing online)

### Exclusion (89)

- Prior Ocular Treatment
- Study Eye:
- Prior treatment with external-beam radiation therapy or transpupillary thermotherapy
- Previous treatment with verteporfin injection (PDT) or corticosteroid IVT injection within 2 years of screening
- Previous laser (except PDT as stated above) used for age related macular degeneration (AMD) treatment  
... and 84 more (see full listing online)

## Locations (50 total)

---

Barnet Dulaney Perkins Eye Center, Mesa, Arizona, United States  
California Retina Consultants, Bakersfield, California, United States  
Retina Associates of Southern California, Huntington Beach, California, United States  
... and 47 more locations